News | Radiopharmaceuticals and Tracers | June 13, 2022

Leading CDMO breaks ground on a 10-acre site that will house multiple particle accelerators designed to produce Ac-225 for the treatment of cancer

SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences industry that specializes in radiopharmaceuticals, today announced that it will showcase its new Actinium-225 production facility during this year’s annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 11-14 in Vancouver, British Columbia, Canada.

June 13, 2022 — SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences industry that specializes in radiopharmaceuticals, today announced that it will showcase its new Actinium-225 production facility during this year’s annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 11-14 in Vancouver, British Columbia, Canada. SpectronRx has secured more than 10-acres in Bunker Hill, Indiana, where it is building a facility that will produce Actinium-225 for the clinical trial and commercial supply of cancer-fighting therapies.

 

“Although there’s currently no Food and Drug Administration-approved treatment using Ac-225, it’s showing great promise when it comes to the treatment of certain types of cancer, including prostate, breast, colon, brain and neuroendocrine,” said John Zehner, CEO of SpectronRx. “Researchers have been studying the radioisotope’s cancer-fighting potential for decades and are on the cusp of several new breakthroughs. Our goal is to support these new therapies as they are approved.”

Actinium-225 is an exceptional cancer fighter. It can be attached to a molecule that delivers the radionuclide to a selectively targeted cancer site, where the Ac-225 alpha-emission can destroy the cancerous tissue with minimum damage to healthy cells. And the high-energy alpha particles Ac-225 releases can interrupt DNA processes, keeping cancer cells from replicating or even killing them altogether. This makes Ac-225 one of the most promising candidates for targeted alpha therapy.

“Unfortunately, there is a limited supply of the Ac-225 radionuclide globally,” said Anwer Rizvi, president of SpectronRx. “This limits the ability of pharmaceutical companies to perform the drug trials needed in order to advance the use of this crucial radionuclide. That’s why building up production of Ac-225 is so important.”

Currently, only small amounts of Ac-225 are being produced by various government entities. To enhance the available supply, SpectronRx will produce Ac-225 through methods including the use of particle accelerators. The company will invest several million dollars to install multiple particle accelerators at its new site near Grissom Air Reserve Base in Indiana, which will produce the much-needed medical isotopes to treat cancer. The project is expected to take two years to complete.

For more information: SpectronRx.com


Related Content

News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
News | RSNA

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
News | Radiopharmaceuticals and Tracers

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Time November 05, 2022
arrow
News | PET Imaging

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
News | PET Imaging

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
News | Radiopharmaceuticals and Tracers

October 6, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time October 06, 2022
arrow
News | Radiopharmaceuticals and Tracers

September 22, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 22, 2022
arrow
Feature | Contrast Media | By Christine Book

The theme “Everyday progress” seems appropriate for the imaging community in 2022. What a year it’s been. Supply ...

Time September 14, 2022
arrow
Subscribe Now